Search results for "Coagulation factor disorder"

showing 1 items of 1 documents

Recombinant factor VIII: past, present and future of treatment of hemophilia A.

2018

The development of recombinant factor VIII (rFVIII) was initially driven by the necessity to treat hemophilia A (HA) patients with FVIII concentrates without the risk of transmitting infectious agents. Over the last three decades the safety of rFVIII has been further improved by completely removing animal or human proteins from the manufacturing process, so that patients would not be exposed to known or emerging pathogens. Recent efforts have concentrated on improving the expression of rFVIII, reducing its immunogenicity and enhancing its pharmacokinetic (PK) behavior. These new goals have been possible thanks to the develop-ment of biotechnology and a better knowledge of the function and s…

0301 basic medicine030204 cardiovascular system & hematologyPharmacologyStandard half-life FVIIIHemophilia ARecombinant factor viiiHemostaticslaw.inventionCoagulation factor disorder03 medical and health sciences0302 clinical medicineHemostaticlawExtended half-life FVIIIMedicineHumansPharmacology (medical)Mode of actionPharmacologyFactor VIIIbiologybusiness.industryManufacturing processImmunogenicityHuman cellRecombinant ProteinRecombinant FVIIIRecombinant Proteins030104 developmental biologyTreatment OutcomeConsumer Product Safetybiology.proteinRecombinant DNAPEGylationAntibodybusinessDrug ContaminationHumanHalf-LifeDrugs of today (Barcelona, Spain : 1998)
researchProduct